Research suggests tofacitinib effectively treats alopecia areata (AA), particularly when used early for severe cases. This offers promising evidence for doctors to consider when making treatment ...

Huang J, Deng S, Li J, et al. Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study. Acta Derm Venereol . 2023;103:adv13475. doi:10.2340/actadv ...

The stigma of having alopecia causes more depression and anxiety than the disease itself, new research has found.

It occurs when a faulty immune system attacks healthy hair follicles. Alopecia universalis is a severe form of alopecia ...

While there have been case reports of topical JAK inhibitors for alopecia areata, larger clinical trials of ruxolitinib 1.5% cream and delgocitinib ointment and tofacitinib 2% ointment have not ...

Problems with a person’s immune system can cause numerous dermatologic conditions including vitiligo, alopecia areata, and atopic dermatitis. Tofacitinib works by blocking a key pathway in the ...

Alopecia areata affects millions of Americans regardless of age, race, or gender, manifesting as patchy hair loss across the scalp and sometimes other body areas. This autoimmune condition occurs ...

New treatment for teens with alopecia. The FDA approved the once-daily pill called Litfulo, created by pharmaceutical giant Pfizer, for people 12 and up to treat severe alopecia areata, or at ...

Alopecia areata affects nearly 2% of the general population at some point in their lifetime, or as many as nearly 7 million people in the United States, ...